Page 49 - textbook5chapters
P. 49

Table 6. Current Clinical trials of HIPEC in Ovarian Cancer

                                   Type/Phase of Study/                                                                         Expected
                                                                                    HIPEC Regimen and Technique Completion Outcome Measures
Setting Cytoreduction              Name                  Location      NCTRN

Recurrence                         Randomised            Rome Italy    NCT01539785 Cisplatin (CDDP) 75 mg/m2      2018  PFI
                                   HORSE                                                     Closed                     OS/ morbidity & mortality
Recurrence                                                                                                                                                                                       Technique of Intraperitoneal Chemotherapy: Normothermic and Hyperthermic 1301
Secondary

Recurrence                         Phase 2               Linz Austria  NCT02487849 Carboplatin 800 mg/m2          2020  Side-effects and postoperative
Secondary                                                                                    Closed                        complications QOL, PFS 2 years

Recurrence                         Phase 3               France        NCT01376752 Cisplatin 75 mg/m2             2018  OS 4 years
Secondary                          Randomised CHIPOR     MSKCC USA                                                2018  PFS 4 years
                                                                       NCT01767675 Carboplatin 800mg/m2
Recurrence                         Phase 2                                                   Closed                     Progression free status,
Secondary                          Randomised                                                                           Toxicity, complications,

                                                                                                                           pharmacokinetics

Frontline                          Phase 3               Italy         NCT01628380  Cisplatin (CDDP) (100 mg/m2)  2018  DFS 2 years
Frontline IDS only                                                                  + Paclitaxel (175 mg/m2)            Mortality/morbidity
                                                                                                                        OS, Time to chemo
                                   Randomised CHORINE                               Closed/open

Frontline                          Phase 3               Netherlands   NCT00426257 Platinum 100 mg/m2             2016  PFS, Toxicity/ morbidity
Secondary/interval debulking       Randomised                                                                           QOL/ OS/ Tumour response

Frontline                          Phase 3               Murcia, Spain NCT02328716 Cisplatin 75 mg/m2             2015  DFS 30 months
                                   Randomised                                                                           OS, morbidity, QOL, ex-vivo studies
                                   CARCINOHIPEC

Frontline Primary only             Phase 2 Randomised    Baltimore USA NCT02124421 Carboplatin AUC=6              2020  30 day post op complication rates
                                                                                                                        QOL, PFS/OS
CRS/HIPEC +IV C 6 vs CRS+IV-IP C6

Any

Frontline/ recurrence              Phase 2/3             Korea         NCT01091636 Cisplatin (75 mg/m2)           2017  PFS 2 years OS, QOL
                                   Randomised                                                                     2018
Frontline/ Recurrence                                    Ghent, Belgium NCT0256725  Cisplatin (75 mg/m2 and             Translational
CRS+IPEC ( 2 doses)                Phase 2 Randomised                                  120 mg/m2)                       Mortality, morbidity, QOL, survival
vs CRS + HIPEC (2 doses)              OvIP1

PFI = progression free interval, PFS= progression free survival, OS = overall survival, QOL= quality of life, CRS = cytoreductive surgery, IPEC = intra peritoneal chemotherapy , IDS= interval
debulking surgery
   44   45   46   47   48   49   50   51   52   53   54